SAN DIEGO--(BUSINESS WIRE)--Mar. 14, 2013--
Illumina, Inc. (NASDAQ: ILMN) today announced that a federal jury in
Tacoma, Washington found that Illumina’s BeadChip array product
infringed U.S. Patent No. 6,951, 682, asserted by Syntrix Biosystems,
Inc. The federal jury ordered Illumina to pay approximately $96 million
in damages to Syntrix based on a royalty rate of six percent for
BeadChip products sold by Illumina from 2005 through May 2012. United
States District Court Judge Benjamin H. Settle, however, dismissed from
the case claims that Illumina’s alleged infringement was willful and
that Illumina misappropriated Syntrix’s trade secrets. The Syntrix
patent expires on September 17, 2019.
Illumina continues to believe that Syntrix’s claims are without merit.
Illumina intends to file post-trial motions asking the court to vacate
the jury’s finding and to rule as a matter of law that the BeadChip does
not infringe Syntrix’s patent.
Jay Flatley, Illumina’s President and CEO, stated, “We strongly disagree
with this verdict and plan to appeal the present finding of
infringement. In the meantime, we will continue to sell the products
that are the subject of this suit and no damages will be payable to
Syntrix until all appropriate appeals have been taken, which may take a
number of years.” Mr. Flatley continued, “Our BeadChip products are
based on Dr. David Walt’s technology that was licensed from Tufts
University when Illumina was founded in 1998. Like many other companies,
we respect the valid and enforceable intellectual property rights of
others. Consistent with our policy, we believe we acted properly with
respect to the Syntrix ‘682 patent. We continue to feel very strongly
about our position that Syntrix’s allegations are without merit and
that, ultimately, our position will be vindicated.”
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward-looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Source: Illumina, Inc.